Clinical Trial Update: A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) [Phase 1]

View source ↗

Summary

A Phase 1 study assessing safety, pharmacokinetics, and activity of the combination of cevostamab and elranatamab in relapsed or refractory multiple myeloma; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Or Refractory Multiple Myeloma

Drugs mentioned

• Cevostamab (cevostamab)
• Elranatamab (elranatamab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Relapsed or Refractory Multiple Myeloma | Phase 1 | Status: RECRUITING